All In Biotech

Drug Trial Radar · NCT04463771

Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

206

Actual

Start

Jan 26, 2021

Primary completion

May 29, 2026

Study completion May 29, 2026

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
Jul 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.

Conditions

  • Endometrial Cancer

Interventions

  • retifanlimabDrug

    INCMGA00012 administered intravenously on Day 1 of each 28-day cycle for up to 26 cycles.

  • epacadostatDrug

    epacadostat will be administered orally BID.

  • pemigatinibDrug

    pemigatinib will be administered orally QD.

  • INCAGN02385Drug

    INCAGN2385 will be administered every 2 weeks

  • INCAGN02390Drug

    INCAGN2390 will be administered every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Group A - Objective Response RateTime frame: up to 2.5 years

Locations

65 sites in 7 countries. Site status is shown where the registry gives one.

  • Alaska Womens Cancer Care Akwcc

    Anchorage, Alaska

  • Honorhealth

    Phoenix, Arizona

  • Arizona Oncology Associates

    Tucson, Arizona

  • UCLA Medical Hematology & Oncology

    Los Angeles, California

  • Olive View Med Ctr

    Sylmar, California

  • Broward Health Medical Center

    Fort Lauderdale, Florida

  • Miami Cancer Institute

    Miami, Florida

  • Mount Sinai Medical Center Comprehensive Cancer Center

    Miami Beach, Florida

  • Advent Health Medical Group-Orlando 2501

    Orlando, Florida

  • H. Lee Moffitt Cancer Center and Research Institute Hospital

    Tampa, Florida

  • Georgia Cancer Center

    Augusta, Georgia

  • Barbara Ann Karmanos Cancer Hospital

    Detroit, Michigan

  • Minnesota Oncology-Maplewood

    Coon Rapids, Minnesota

  • Midwest Cancer Care

    Kansas City, Missouri

  • Washington University

    St Louis, Missouri

  • Billings Clinic Cancer Center

    Billings, Montana

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • New Mexico Cancer Care Alliance

    Albuquerque, New Mexico

  • Laura & Isaac Perlmutter Cancer Ctr

    New York, New York

  • University of North Carolina At Chapel Hill

    Chapel Hill, North Carolina

  • The Ohio State University Wexner Medical Center Division of Gynecologic Oncology

    Hilliard, Ohio

  • Willamette Valley Cancer Institute

    Eugene, Oregon

  • Texas Oncology-Tyler

    Sioux Falls, South Dakota

  • Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology-Austin Center

    Austin, Texas

  • Texas Oncology-Fort Worth South Henderson

    Fort Worth, Texas

  • Texas Oncology San Antonio

    San Antonio, Texas

  • Texas Oncology the Woodlands

    Shenandoah, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • O.L.V Ziekenhuis

    Aalst, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • Ghent University Hospital

    Ghent, Belgium

  • Universitaire Ziekenhuis Leuven - Gasthuisberg

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liege - Sart Tilman

    Liège, Belgium

  • Chu Ucl Namur de Saint Elisabeth

    Namur, Belgium

  • Chu Besancon Hospital Jean Minjoz

    Besançon, France

  • Institut Bergonie

    Bordeaux, France

  • Hospital Cochin Cancerologie

    Paris, France

  • Cario - Centre Armoricain de Radiotherapie Imagerie Medicale Et Oncologie

    Plérin, France

  • Centre de Lutte Contre Le Cancer - Institut de Cancerologie de L'Ouest - Rene Gauducheau

    Saint-Herblain, France

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.